Results 61 to 70 of about 51,886 (205)

TET2 inhibits differentiation of embryonic stem cells but does not overcome methylation-induced gene silencing [PDF]

, 2014
TET2 is a methylcytosine dioxygenase that is frequently mutated in myeloid malignancies, notably myelodysplasia and acute myeloid leukemia. TET2 catalyses the conversion of 5′-methylcytosine to 5′-hydroxymethylcytosine within DNA and has been implicated ...
Chevassut, Timothy, Norman, Louis, Tarrant, Paul   +2 more
core   +3 more sources

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. [PDF]

, 2009
Progress in the management of patients with myelodysplastic syndromes (MDS) has been hampered by the inability to detect cytogenetic abnormalities in 40-60% of cases.
Bueso-Ramos, CE, Estey, EH, Garcia-Manero, G, Gilliland, DG, Heinrichs, S, Issa, J-P, Kantarjian, HM, Kornblau, SM, Kulkarni, RV, Levine, RL, Li, C, Loh, ML, Look, AT, Neuberg, D   +13 more
core   +1 more source

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes

Haematologica, 2013
Interstitial deletion of chromosome 5q is the most common chromosomal abnormality in myelodysplastic syndromes. The catalogue of genes involved in the molecular pathogenesis of myelodysplastic syndromes is rapidly expanding and next-generation sequencing
Marta Fernandez-Mercado, Adam Burns, Andrea Pellagatti, Aristoteles Giagounidis, Ulrich Germing, Xabier Agirre, Felipe Prosper, Carlo Aul, Sally Killick, James S. Wainscoat, Anna Schuh, Jacqueline Boultwood   +11 more
doaj   +1 more source

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation [PDF]

, 2017
The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis.
Alessandrino, E.P., Beelen, D.W. (Dietrich), Biezen, A. (Anja) van, Cahn, J.Y. (J. Y.), Chevallier, P. (Patrice), Cornelissen, J.J. (Jan), Crawley, C. (C.), de Wreede, L.C. (Liesbeth C.), Finke, J. (Jürgen), Göhring, G. (Gudrun), Itälä Remes, M. (Maija), Koenecke, C. (Christian), Kröger, N. (Nicolaus), Ljungman, P., Maertens, J. (Johan), Milpied, N., Mufti, G.J. (Ghulam), Passweg, J. (Jakob Robert), Peniket, A. (A.), Petersen, E.J. (Eefke), Richard Espiga, C. (Carlos), Robin, M. (Marie), Russell, N. (Nigel), Scheid, C. (Christof), Sierra, J. (Jorge), Veelken, J. (Joan), Volin, L. (Liisa), Witte, T. de   +27 more
core   +1 more source

Therapy-related myeloid neoplasms following treatment with radioiodine

Haematologica, 2012
Background Few data are available on therapy-related myelodysplastic syndromes and acute myeloid leukemia developing after radioiodine treatment.Design and Methods We retrospectively analyzed 39 patients with myeloid neoplasms following radioiodine ...
Thomas Schroeder, Andrea Kuendgen, Sabine Kayser, Nicolaus Kröger, Friederike Braulke, Uwe Platzbecker, Viola Klärner, Fabian Zohren, Detlef Haase, Michael Stadler, Richard Schlenk, Akos G. Czibere, Ingmar Bruns, Roland Fenk, Norbert Gattermann, Rainer Haas, Guido Kobbe, Ulrich Germing   +17 more
doaj   +1 more source

Comparison of I-FISH and G-banding for the detection of chromosomal abnormalities during the evolution of myelodysplastic syndrome [PDF]

, 2009
Myelodysplastic syndrome (MDS) patients with a normal karyotype constitute a heterogeneous group from a biological standpoint and their outcome is often unpredictable. Interphase fluorescence in situ hybridization (I-FISH) studies could increase the rate
Chauffaille, Maria de Lourdes Lopes Ferrari, Pinheiro, R.f.   +1 more
core   +2 more sources

Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia

Haematologica, 2018
Mesenchymal stromal cells are involved in the pathogenesis of myelodysplastic syndromes and acute myeloid leukemia, but the underlying mechanisms are incompletely understood.
Stefanie Geyh, Manuel Rodríguez-Paredes, Paul Jäger, Annemarie Koch, Felix Bormann, Julian Gutekunst, Christoph Zilkens, Ulrich Germing, Guido Kobbe, Frank Lyko, Rainer Haas, Thomas Schroeder   +11 more
doaj   +1 more source

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene [PDF]

, 2015
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with
Al, M.J. (Maiwenn), Armstrong, N. (Nigel), Blommestein, H.M. (Hedwig), Deshpande, S. (Sohan), Kleijnen, J.M.P. (Jos), Noake, C. (Caro), Riemsma, R. (Rob), Ryder, S. (Steve), Severens, J.L. (Hans), Worthy, G. (Gill)   +9 more
core   +5 more sources

The myelodysplastic syndromes [PDF]

Clinical & Laboratory Haematology, 2008
Clinicomorphological features of myelodysplastic syndromes, Antonio Pagliuca and Ghulam J. Mufti FAB and MIC classification of myelodysplastic syndromes - points of controversy, John M. Bennett incidence and epidemiology of the myelodysplastic syndromes, R. A. Cartwright pathogenesis and evolution of refractory anaemia, A. Jacobs and D.
openaire   +2 more sources

Emerging Therapies for the Myelodysplastic Syndromes

Clinical Hematology International, 2019
Despite considerable advances in our understanding of the molecular and epigenetic underpinnings of the myelodysplastic syndromes (MDS), this diverse group of myeloid neoplasms remains a significant clinical challenge.
Jonathan Canaani
doaj   +1 more source